<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134897</url>
  </required_header>
  <id_info>
    <org_study_id>RuCorT-02</org_study_id>
    <nct_id>NCT04134897</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer</brief_title>
  <acronym>RuCorT-02</acronym>
  <official_title>A Multicenter Prospective Phase III Clinical Trial of Neoadjuvant CapOx in Patients With Intermediate Risk CRM-negative Middle Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 3 months of neoadjuvant CapOx is
      non-inferior to neoadjuvant radiotherapy in patients with moderate risk CRM&quot;-&quot; mid rectal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of neoadjuvant chemotherapy compared to 5x5 Gy
      neoadjuvant radiotherapy in moderate risk CRM-negative rectal cancer patients. This is a
      prospective multicenter open-label non-inferiority randomized phase III clinical trial.
      Patients will be randomized using an online randomization system to receive either 4 cycles
      of neoadjuvant CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days
      1-14) chemotherapy, surgery and 4 cycles of adjuvant CapOx chemotherapy or 5x5 Gy
      radiotherapy, surgery and 8 cycles of adjuvant CapOx chemotherapy. A stratification will be
      performed based on сN stage and clinical center. Patients with сT3c-T3dN0-1M0, cT1-T3dN2M0
      cancer in the middle rectum are included. Chemoradiotherapy (50 Gy with concomitant
      capecitabine 825 mg/m2 per os bid on radiation days) will be performed for patients with
      tumor progression after neoadjuvant chemotherapy. The main hypothesis is that the 2-year
      local recurrence rate is non-inferior after neoadjuvant chemotherapy and neoadjuvant
      radiotherapy in moderate risk mid rectal cancer patients. The target accrual is 158 patients
      in each treatment arm (including 10% potential data loss) based on non-recurrence rate of 98%
      in investigated and 96% in the control group with a non-inferiority margin of 3%, α=0,05,
      power 80%. An interim analysis is planned after 50% of the patients will reach a 2-year
      followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for staging
      before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI is subject to
      central review. Conduction of this study and data collection are controlled by a local
      institutional board.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year local recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjuvant chemotherapy compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who receive a complete course of adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute chemotherapy toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate (pCR)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity measured according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant chemotherapy disease progression rate</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with disease progression during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative tumor-associated complications rate</measure>
    <time_frame>3 months</time_frame>
    <description>The rate of tumor-associated complications (bowel obastruction, bleeding etc) during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Rectal Neoplasms Malignant</condition>
  <condition>Rectum Carcinoma</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2, bid, per os, days 1-14, 4 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 iv day 1, 4 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal cancer surgery</intervention_name>
    <description>Laparoscopic or open total mesorectal excision</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions</description>
    <arm_group_label>Neoadjuvant radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically verified colon rectal adenocarcinoma

          -  сT3c-T3dN0-1M0, cT1-T3dN2M0. cancer of the middle rectum (based on pelvic MRI)

          -  Tumor more than 2 mm from mesorectal fascia (based on pelvic MRI)

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Haemoglobin (HGB) &gt; 90 g/L

          -  Platelet Count (PLT) &gt; 120x10*9/L

          -  Serum creatinine &lt; 150 µmol/L

          -  Total bilirubin &lt; 25 µmol/L

        Exclusion Criteria:

          -  inability to obtain informed consent

          -  distant metastases

          -  synchronous or metachronous tumors

          -  previous chemotherapy or radiotherapy

          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg

          -  clinically significant neurological disorders

          -  previous neuropathy 2 or higher

          -  current infection or heavy systemic disease

          -  pregnancy, breastfeeding

          -  ulcerative colitis

          -  individual intolerance to treatment components

          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency

          -  participation in other clinical trials

          -  psychiatric disorders, which render patient unable to follow instructions or
             understand his/her condition

          -  technical inability to perform pelvic MRI

          -  inability of long-term followup of the patient

          -  HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaman Z Mamedli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N.Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator, Consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>neoadjuvant radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

